GNS Healthcare Inc., of Cambridge, Mass., said it raised $23 million in a series D fundraising led by Cigna Ventures, a wholly owned indirect subsidiary of Cigna Corp., with participation from Amgen Ventures, Celgene Corp., Echo Health Ventures, Alexandria Venture Investments and former Caesar's CEO and Aetna Division President Gary Loveman. 

Cytomx Therapeutics Inc., of South San Francisco, will receive a $10 million payment from Abbvie Inc., of North Chicago, for the selection of a second target under their 2016 collaboration to discover and develop Probody drug conjugates.

Batavia Biosciences BV, of Leiden, the Netherlands, received a follow-up grant of $2.2 million from the global nonprofit Path, to develop and manufacture novel oral poliovirus vaccines. 

The U.S. Court of Appeals for the Federal Circuit Friday unsealed its decision in the patent lawsuit between Enzo Life Sciences Inc. and a group of defendant-appellees led by Roche Molecular Systems Inc., affirming a lower court's decision to grant summary judgment against Enzo for lack of enablement of the disputed patent claims. 

Oncosenx Inc., of Seattle, said it raised $3 million in pre-seed funding to advance its pipeline. The company is developing a selective tumor-killing platform with two main components: a proprietary lipid nanoparticle for cellular delivery and a selective DNA payload. 

Novelion Therapeutics Inc., of Vancouver, British Columbia, received written notice from Nasdaq that it is not in compliance with the continued listing requirement to maintain minimum market value of publicly held shares of $15 million.